Fair‐Weather Friends: Evidence of Lipoxin Dysregulation in Neurodegeneration
Authors:
- 7 January 2020
- journal article
- review article
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 64 (4) , e1801076
Abstract
Lipoxins (LXs) are autacoids, specialized proresolving lipid mediators (SPMs) acting locally in a paracrine or autocrine fashion. They belong to a complex superfamily of dietary small polyunsaturated fatty acid (PUFA)–metabolites, which direct potent cellular responses to resolve inflammation and restore tissue homeostasis. Together, these SPM activities have been intensely studied in systemic inflammation and acute injury or infection, but less is known about LX signaling and activities in the central nervous system. LXs are derived from arachidonic acid, an omega‐6 PUFA. In addition to well‐established roles in systemic inflammation resolution, they have increasingly become implicated in regulating neuroinflammatory and neurodegenerative processes. In particular, chronic inflammation plays a central role in Alzheimer's disease (AD) etiology, and dysregulated LX production and activities have been reported in a variety of AD rodent models and clinical tissue samples, yet with complex and sometimes conflicting results. In addition, reduced LX production following retinal injury has been reported recently by the authors, and an intriguing direct neuronal activity promoting survival and homeostasis in retinal and cortical neurons is demonstrated. Here, the authors review and clarify this growing literature and suggest new research directions to further elaborate the role of lipoxins in neurodegeneration.Keywords
Funding Information
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada
- National Eye Institute (EY026082)
This publication has 96 references indexed in Scilit:
- Proresolution Lipid Mediators in Multiple Sclerosis — Differential, Disease Severity-Dependent Synthesis — A Clinical Pilot TrialPLOS ONE, 2013
- Anti-inflammatory lipoxin A4is an endogenous allosteric enhancer of CB1cannabinoid receptorProceedings of the National Academy of Sciences, 2012
- Glial cells in (patho)physiologyJournal of Neurochemistry, 2012
- RETRACTED: Transcriptional regulation of βsecretase‐1 by 12/15‐lipoxygenase results in enhanced amyloidogenesis and cognitive impairmentsAnnals of Neurology, 2011
- Profile of Lipid and Protein Autacoids in Diabetic Vitreous Correlates With the Progression of Diabetic RetinopathyDiabetes, 2010
- Lipoxins: resolutionary roadBritish Journal of Pharmacology, 2009
- Selective Survival Rescue in 15-Lipoxygenase-1-deficient Retinal Pigment Epithelial Cells by the Novel Docosahexaenoic Acid-derived Mediator, Neuroprotectin D1Journal of Biological Chemistry, 2009
- Increased 5-Lipoxygenase Immunoreactivity in the Hippocampus of Patients With Alzheimer's DiseaseJournal of Histochemistry & Cytochemistry, 2008
- Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediatorsNature Reviews Immunology, 2008
- 5‐Lipoxygenase gene disruption reduces amyloid‐β pathology in a mouse model of Alzheimer's diseaseThe FASEB Journal, 2007